Latest News

Sesen Bio to Host Conference Call to Review First Quarter 2019 Financial Results and Updated Preliminary Data from Phase 3 VISTA Trial

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sesen Bio (Nasdaq:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Company management will host a conference call and webcast on Monday, May 13, 2019 at 8:00 a.m. EDT to review operating results for the first quarter ended March 31, 2019 and updated, preliminary primary and new secondary endpoint data from the Phase 3 VISTA trial of Vicinium® for patients with h

Source link

Related posts

Arm cuff BP measurements may fall short for predicting heart disease risk in some people with resistant high BP


Nearly a quarter of antibiotic prescriptions for children and adults may be unnecessary


Incoming Sláintecare Chief resigns directorship at HSE contractor


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy